arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Cardiff Oncology, Inc.

CRDF
$1.00 ▲ +0.03 (+2.67%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
107 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

Cardiff Oncology, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $68.3M
Dividend Yield
Revenue Growth -62.4%
Op. Margin None
ROIC -29.2%
FCF / Share $-0.18
Trailing P/E
Price / Book 2.0x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

107-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$41.00K
↓ -62.4%
Net Income Profit after all expenses
$-12.35M
↑ +8.1%
FCF / Share Free cash flow per share
$-0.18
↑ +6.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
8
Cash Quality
56

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 27 years · 107 quarters